Members of the G protein-coupled receptor family of integral membrane proteins, the LPL Receptor (Lysophospholipid Receptor) group are crucial for lipid signaling. There are eight LPL receptors in humans, and different genes each encode one of them. Other names for these LPL receptor genes include "Edg." In the cell membrane, LPL receptor ligands bind to and activate their corresponding receptors. The activated receptor can have a variety of effects on the cell, depending on the ligand, receptor, and type of cell involved. These include primary effects such as adenylyl cyclase inhibition and calcium release from the endoplasmic reticulum, as well as secondary effects such as cell proliferation and apoptosis prevention. Type: S1PR1, S1PR2, S1PR3, S1PR4, S1PR5, LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V76507 | SLB1122168 formic | SLB1122168 formic is a potent inhibitor of Spns2-mediated S1P release with IC50 of 94 nM. | ||
V75442 | Sonepcizumab (LT 1009; Anti-Human S1P Recombinant Antibody) | 1031360-18-5 | Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody (mAb). | |
V81428 | Spns2-IN-1 | Spns2-IN-1 is a potent inhibitor of Spns2-dependent S1P transport (Spns2) with IC50 of 1.4±0.3 μM and plays an important role in immune responses. | ||
V75457 | TAK-615 | 1664335-55-0 | TAK-615 is a NAM (negative allosteric modulator) of the LPA1 receptor used to study pulmonary fibrosis. | |
V75445 | Tamuzimod | 2097854-81-2 | Tamuzimod is a potent immunomodulator. | |
V75449 | Zectivimod | 1623066-63-6 | Zectivimod is a sphingosine-1-phosphate receptor agonist. | |
V40955 | 1-O-9Z-Octadecenoyl-sn-glyceryl-3-phosphoricacidsodiumsalt | 325465-93-8 | Lysophosphatidic acid is an endogenous agonist of the lysophospholipid receptors LPA1 and LPA2, a glycerophospholipid signaling ligand molecule and ligand activator for EDG-2, EDG-4, and EDG-7. |